Combination of palladium nanoparticles and tubastatin-A potentiates apoptosis in human breast cancer cells: a novel therapeutic approach for cancer.

摘要: Background Breast cancer is the most common malignant disease that occurs in women. Histone deacetylase (HDAC) inhibition has recently emerged as an effective and attractive target for treatment of cancer. The aim this study was to investigate efficacy a combined tubastatin A (TUB-A) palladium nanoparticles (PdNPs) against MDA-MB-231 human breast cells using two different cytotoxic agents work by mechanisms, thereby decreasing probability chemoresistance increasing toxicity, provide efficient therapy advanced stage without any undesired side effects. Methods PdNPs were synthesized novel biomolecule called R-phycoerythrin characterized various analytical techniques. combinatorial effect TUB-A assessed cellular biochemical assays also gene expression analysis. Results biologically had average size 25 nm spherical shape. Treatment with or showed dose-dependent on cell viability. combination 4 μM significant inhibitory viability compared either alone. more pronounced HDAC activity enhanced apoptosis regulating changes. Conclusion Our results suggest there strong synergistic interaction between cells. These data important preclinical basis future clinical trials drug combination. This increased therapeutic potentials, demonstrating relevant targeted Furthermore, we have provided first evidence mechanism toxicity novelties identification consists suitable molecules kill exploration possible mechanisms involved reduce